MENU
+Compare
XLO
Stock ticker: NASDAQ
AS OF
Jun 3, 04:59 PM (EDT)
Price
$0.67
Change
-$0.03 (-4.29%)
Capitalization
35M

XLO Xilio Therapeutics Forecast, Technical & Fundamental Analysis

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments... Show more

XLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for XLO with price predictions
Jun 02, 2025

Aroon Indicator for XLO shows an upward move is likely

XLO's Aroon Indicator triggered a bullish signal on May 19, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 36 similar instances where the Aroon Indicator showed a similar pattern. In of the 36 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for XLO crossed bullishly above the 50-day moving average on May 14, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where XLO advanced for three days, in of 142 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for XLO moved out of overbought territory on May 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 38 cases where XLO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on June 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XLO as a result. In of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XLO turned negative on June 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at .

XLO moved below its 50-day moving average on June 02, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XLO broke above its upper Bollinger Band on May 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XLO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.271) is normal, around the industry mean (17.331). P/E Ratio (0.000) is within average values for comparable stocks, (59.245). XLO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (4.753) is also within normal values, averaging (261.682).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
XLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

XLO is expected to report earnings to fall 4.39% to -17 cents per share on August 06

Xilio Therapeutics XLO Stock Earnings Reports
Q2'25
Est.
$-0.17
Q1'25
Missed
by $0.37
Q4'24
Beat
by $0.06
Q3'24
Beat
by $0.03
Q2'24
Missed
by $0.01
The last earnings report on May 08 showed earnings per share of -18 cents, missing the estimate of 18 cents. With 2.27M shares outstanding, the current market capitalization sits at 35.00M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
828 Winter Street
Phone
+1 857 524-2466
Employees
73
Web
https://www.xiliotx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CMCO14.901.10
+7.97%
Columbus McKinnon Corp
PAYX158.250.75
+0.48%
Paychex
TISI19.090.03
+0.16%
Team
ACT34.90-0.09
-0.26%
Enact Holdings
OLMA4.05-0.32
-7.43%
Olema Pharmaceuticals

XLO and Stocks

Correlation & Price change

A.I.dvisor tells us that XLO and CRMD have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XLO and CRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XLO
1D Price
Change %
XLO100%
-34.57%
CRMD - XLO
31%
Poorly correlated
+4.61%
AXON - XLO
31%
Poorly correlated
+1.09%
VKTX - XLO
30%
Poorly correlated
-2.54%
AVTX - XLO
27%
Poorly correlated
+8.75%
AIMD - XLO
26%
Poorly correlated
-6.47%
More